Which of the following Oxybutynin formulations is indicated for the symptoms of detrusor overactivity associated with a condition called Spina bifida?
 
I. Ditropan
II. Oxytrol
III. Ditropan XL
 
a. I only
b. III only
c. I and II only
d. II and III only
e. All
 
Answer: (b). Oxybutynin (Ditropan XL) is an antispasmodic, anticholinergic agent. Each Oxybutynin (Ditropan XL) Extended Release Tablet contains 5 mg, 10 mg, or 15 mg of Oxybutynin chloride USP, formulated as a once-a-day controlled-release tablet for oral administration. Oxybutynin (Ditropan XL) uses osmotic pressure to deliver oxybutynin chloride at a controlled rate over approximately 24 hours.
 
Oxybutynin (Ditropan XL) is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. It is also indicated in the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).
 
Oxybutynin (Ditropan XL) must be swallowed whole with the aid of liquids, and must not be chewed, divided, or crushed. It may be administered with or without food. The recommended starting dose of Oxybutynin (Ditropan XL) in adult is 5 or 10 mg once daily at approximately the same time each day. Dosage may be adjusted in 5-mg increments to achieve a balance of efficacy and tolerability (up to a maximum of 30 mg/day).
 
For pediatric patients aged 6 years of age and older, the recommended starting dose of Oxybutynin (Ditropan XL) is 5 mg once daily at approximately the same time each day. Dosage may be adjusted in 5-mg increments to achieve a balance of efficacy and tolerability (up to a maximum of 20 mg/day).
 
Dry mouth, constipation, blurred vision and vasodilation are commonly reported side effects of Oxybutynin (Ditropan XL).
 
Try Naplex QBank. www.pharmacyexam.com